新聞稿

TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), presented new data from niraparib programs at American Society of Clinical Oncology (ASCO) Annual Meeting 2019, which was held from May 31 to June 4 in Chicago, Illinois.

Oral presentation:

Combination of niraparib and bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer. A proof-of concept randomized controlled chemotherapy-free study: NSGO AVANOVA2/ENGOT-OV24

Category: Gynecologic Cancer

Abstract No: 5505

Posters:

IOLite: multipart, phase 1b, dose-finding study of the PD-1 Inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer

Category: Developmental Immunotherapy and Tumor Immunobiology

Abstract No: 2560

Poster Board Number: Poster Session (Board #204)

Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by HRR mutational gene profile analysis

Category: Gynecologic Cancer

Abstract No: 5568

Poster Board Number: Poster Session (Board #391)

Risk factors for progression or death in ovarian cancer patients who completed first line platinum treatment

Category: Gynecologic Cancer

Abstract No: 5548

Poster Board Number: Poster Session (Board #371)

Recurrence of Ovarian Cancer in BRCAwt Patients Without Maintenance Therapy: Real-World Evidence

Category: Gynecologic Cancer

Abstract No: 5547

Poster Board Number: Poster Session (Board #370)

ENGOT-OV44/FIRST study: a randomized, double-blind, phase 3 study of platinum-based therapy with TSR-042 + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 nonmucinous epithelial ovarian cancer (OC)

Category: Gynecologic Cancer

Abstract No: TPS5600

Poster Board Number: Poster Session (Board #420a)

Real world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients

Category: Gynecologic Cancer

Abstract No: 5579

Poster Board Number: Poster Session (Board #402)

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT03431350)

Category: Genitourinary (Prostate) Cancer

Abstract No: TPS5087

Poster Board Number: Poster Session (Board #198b)

Plasma DNA repair deficient (DRD) status associates with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/ dexamethasone (+P/D)

Category: Genitourinary (Prostate) Cancer

Abstract No: 5066

Poster Board Number: Poster Session (Board #178)

ENGOT-Ov41/ GEICO-69-O/ ANITA trial: a phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (AT) followed by niraparib maintenance with or without AT in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months

Category: Gynecologic Cancer

Abstract No: TPS5599

Poster Board Number: Poster Session (Board #419b)

Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): a phase 2 trial

Category: Gastrointestinal (Noncolorectal) Cancer

Abstract No: TPS4168

Poster Board Number: Poster Session (Board #259b)

A Randomized Phase II Trial of Niraparib Plus Either Nivolumab or Ipilimumab in Patients With Advanced Pancreatic Cancer Whose Cancer Has Not Progressed on Platinum-Based Therapy

Category: Gastrointestinal (Noncolorectal) Cancer

Abstract No: TPS4161

Poster Board Number: Poster Session (Board #256a)

About TESARO

TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.